Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Temozolomide in Stage II-III Acral Melanoma
NCT05512481Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Started Sep 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT05512481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512481.